Cargando…

Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

Lack of consensus for first‐line marginal zone lymphoma (MZL) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first‐l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becnel, Melody R., Nastoupil, Loretta J., Samaniego, Felipe, Davis, Richard E., You, M. J., Green, Michael, Hagemeister, Fredrick B., Fanale, Michelle A., Fayad, Luis E., Westin, Jason R., Wang, Michael, Oki, Yasuhiro, Forbes, Sheryl G., Feng, Lei, Neelapu, Sattva S., Fowler, Nathan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Haematological Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619290/ https://www.ncbi.nlm.nih.gov/pubmed/30919940 http://dx.doi.org/10.1111/bjh.15843

Ejemplares similares

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
por: Feldman, Tatyana, et al.
Publicado: (2014)

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
por: Chiu, Hsiling, et al.
Publicado: (2019)

P1092: A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA
por: Strati, Paolo, et al.
Publicado: (2023)

Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
por: Arcaini, Luca, et al.
Publicado: (2017)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2018)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
por: Gandhi, Anita K, et al.
Publicado: (2014)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Continuous treatment with lenalidomide and low‐dose dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial
por: Lu, Jin, et al.
Publicado: (2017)

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
por: Goy, Andre, et al.
Publicado: (2015)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up
por: Ludwig, Heinz, et al.
Publicado: (2015)

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

SIRPα(+) macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
por: Marques-Piubelli, Mario L., et al.
Publicado: (2022)

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
por: Stuart, Robert K, et al.
Publicado: (2015)

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN)
por: Gandhi, Anita K, et al.
Publicado: (2014)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
por: Zhu, Jun, et al.
Publicado: (2022)

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
por: Sawas, Ahmed, et al.
Publicado: (2017)

Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
por: Siegel, David S., et al.
Publicado: (2019)

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis
por: Chihara, Dai, et al.
Publicado: (2018)

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS
por: Steiner, R., et al.
Publicado: (2022)

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
por: Sborov, Douglas W., et al.
Publicado: (2022)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)
por: Maruyama, Dai, et al.
Publicado: (2020)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
por: Thieblemont, Catherine, et al.
Publicado: (2019)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Splenic marginal zone lymphoma in Sweden 2000–2020: Increasing rituximab use and better survival in the elderly
por: Junlén, Henna‐Riikka, et al.
Publicado: (2023)

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma
por: Chihara, Dai, et al.
Publicado: (2018)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

Transformed mucosa‐associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction‐based clonality analysis
por: Kiesewetter, Barbara, et al.
Publicado: (2019)

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
por: Jagannath, Sundar, et al.
Publicado: (2018)

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis
por: Gupta, Neeraj, et al.
Publicado: (2016)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
por: Sharman, Jeff P., et al.
Publicado: (2016)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

Early‐stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long‐term patient outcomes
por: Parsons, Susan K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cnffvqrjug7el2eunn73l2km65